US OptionsDetailed Quotes
CELU241220P1000
- 0.00
- 0.000.00%
15min DelayTrading Dec 12 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV56.33%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.58Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Celularity Stock Discussion
Sign in to post a comment
NOTE: I don’t have time to include those in my watchlist which didnt run. Just go back to it because those stocks will go usually after days or a week.
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
Sorry I am sleepy cant finish the list.
$Rigetti Computing (RGTI.US)$ PR today 12/10: Quantum Machines And Rigetti Computing Announces The Application Of AI To Automate The Calibration Of A Quantum Computer. Up after hours. SI 13.89%, 0 shares LTB✅
$SEALSQ Corp (LAES.US)$ PR 12/10: Partnership with IC’ALPS to ...
63
11
5
$Celularity (CELU.US)$
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Tuesday, 10th December at 8:00 am
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing ...
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
Tuesday, 10th December at 8:00 am
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing ...
2
$MSP Recovery (LIFW.US)$ Ticker change to MSPR Monday to consolidate services. Even with negative profit margin, of note, company had $10M settlements from property and casualty insurers and acquired Medicare claims valued $10.6B. Low float. Currently trading above 10/20 EMA suggesting short term bullishness. SI 162%, 0 shares LTB
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
$Roth CH Acquisition V Co(Delisted) (ROCL.US)$ Ticker change tomorr...
50
25
6
$Celularity (CELU.US)$
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Friday, 6th December at 8:00 am
• Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings
• Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same perio...
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Friday, 6th December at 8:00 am
• Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings
• Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same perio...
1
1
$Celularity (CELU.US)$ Press Release: Celularity Reports Over Sevenfold Growth in Net Product Sales Through Third Quarter 2024 Compared to Third Quarter 2023
Dow Jones· just
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
-- Celularity filed its Quarterly Report on Form 10-Q for the period ended
September 30, 2024, and is now current with its quarterly report filings
-- Reported Total Net Revenue for the Three Months an...
Dow Jones· just
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
-- Celularity filed its Quarterly Report on Form 10-Q for the period ended
September 30, 2024, and is now current with its quarterly report filings
-- Reported Total Net Revenue for the Three Months an...
what’s so attractive about this company stock$Celularity (CELU.US)$ Celularity's Strategic Partner Announces Groundbreaking For Stem Cell & Regenerative Medicine Center In Asia Pacific
Benzinga· 3 mins ago
Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific regionGenting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
Strategic par...
Benzinga· 3 mins ago
Celularity is collaborating with its strategic partner, Genting Berhad, to bring Celularity placenta-derived allogeneic stem cell therapeutics to the Asia Pacific regionGenting Berhad announced groundbreaking on a new, state-of-the-art wellness and health center in Bali, Indonesia, that will utilize Celularity products
Strategic par...
4
$Celularity (CELU.US)$ buy now price will go up to 4
1
No comment yet
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...